Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Tcs Ltd 1831.20 0.03
Icici Ba 290.30 0.75
Tata Mot 312.25 1.13
State Ba 275.40 0.52
Tata Stl 563.40 0.84
Clear All Clear Last
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
FII Activity
Mutual Fund Activity
Results Watch
Results Calendar
Results Announced
IPO Watch
Recent News
Broker Research
Research Tutorial
Discussion Forum
Research Reports
Sector Watch
Economy Watch
Sun Pharmaceutical Industries Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
Market Lot: 1Face Value: 1ISIN Demat: INE044A01036
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

Business Profile
Sun Pharma (SUNPHARMA) is into specialty pharmaceuticals and active pharmaceutical ingredients. The company operates in select therapeutic segments like psychiatry, neurology, cardiology and gastroenterology. As many as eight bulk actives and 18 processes for DMFs have been developed and scaled up. In all, the company has received seven DMFs and nine EDMFs.

The company doubled its capacity and the area at the bulk active site in Panoli. With the completion of this expansion, 269,000 sq. ft. area has been added to the plant thereby offering additional 129 KL reactor capacity for the regulated markets.

The company plans to work on various technologies in NDDS and work on specific therapy areas for NCE. For products that are differentiated for the medium term, it would continue to work on technologically complex products such as liposome delivery systems, microspheres based delivery systems and controlled release technologies.

The company announced fall of 24.30% in consolidated net profit on y-o-y basis to Rs 13.09 billion, while total income declined 100.00% y-o-y basis to Rs 0.00 million for the quarter ended March 2018.

Recent Developments
Sun Pharmaceutical Industries today announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018.

Sun Pharmaceutical Industries announced a small rise in consolidated net profit for the quarter ended March 2018. During the quarter, the profit of the company rose 6.97% to Rs 13,089.60 million from Rs 12,237.10 million in the same quarter last year.

Sun Pharmaceutical Industries and Churchill Pharmaceuticals, LLC. (Churchill) announced that one of Sun Pharma???s wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA)

owned subsidiaries has launched in US, the Authorized Generic (AG) version for Daiichi Sankyo Inc.'s Welchol (colesevelam hydrochloride) 625mg tablets.

Sun Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA??? (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA??? selectively binds

Sun Pharmaceutical Industries announced that its wholly owned subsidiaries have reached an agreement with Ironwood Pharmaceuticals, Inc. and Allergan plc (together known as the Companies) to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Linzess (Linaclotide capsules) in the US.

Sun Pharmaceutical Industries announces that the US FDA has accepted a New Drug Application (NDA), filed by its wholly owned subsidiary, for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%, a novel nanomicellar formulation of cyclosporine A 0.09% in

Sun Pharmaceutical Industries today announced that one of its wholly owned subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Coreg CR, (carvedilol phosphate) extended release capsules, 10mg, 20mg, 40mg, 80 mg.

In Brief

Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited